NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) today announced that the English version of the Annual report for 2019 is now available on the company’s website, www.neurovive.com.
NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, has announced that the company's share has been upgraded to trading on the OTC Market Group's best market, OTCQX in the US. The ...
Full speed ahead First Quarter (1 Jan. 2016 – 31 Mar. 2016)Net revenues were SEK 0 (0) and other operating income was SEK 46,000 (49,000).Loss before tax was SEK 10,916,000 (14,271,000).Earnings per s ...
NeuroVive Pharmaceutical AB (publ) announces that registration of the preferential rights issue totaling SEK 94.4 m has now been completed, and provides an updated timeline for the conversion of Neuro ...
NeuroVive Pharmaceutical AB (publ) has completed the preferential rights issue of units, comprising shares and warrants, authorized by the Extraordinary General Meeting on 31 March 2016. The preferent ...
NeuroVive Pharmaceutical AB (publ) held its Annual General Meeting (AGM) yesterday, 28 April 2016. A summary of the resolutions follows. All resolutions were passed with the required majority.
NeuroVive Pharmaceutical AB (publ), the pioneers in mitochondrial medicine, will present important research findings together with researchers at Lund University in three scientific poster presentatio ...
Cookies
We serve cookies. If you think that's ok, just click "Accept all". You can also choose what kind of cookies you want by clicking "Settings".
Read our cookie policy